Alnylam Pharmaceuticals, Inc. (ALNY)
Automate Your Wheel Strategy on ALNY
With Tiblio's Option Bot, you can configure your own wheel strategy including ALNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALNY
- Rev/Share 18.1074
- Book/Share 0.8902
- PB 350.8503
- Debt/Equity 11.2759
- CurrentRatio 3.0385
- ROIC -0.0279
- MktCap 40722780160.0
- FreeCF/Share -0.5813
- PFCF -540.1974
- PE -150.1678
- Debt/Assets 0.3089
- DivYield 0
- ROE -5.0933
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ALNY | Redburn Atlantic | -- | Buy | -- | $353 | March 31, 2025 |
| Upgrade | ALNY | JP Morgan | Neutral | Overweight | $280 | $328 | March 24, 2025 |
| Initiation | ALNY | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Upgrade | ALNY | Goldman | Neutral | Buy | $198 | $370 | Aug. 16, 2024 |
News
Alnylam Pharmaceuticals Names Garg R&D Chief
Published: June 18, 2025 by: Market Watch
Sentiment: Neutral
Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.
Read More
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
Published: June 18, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA® in transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam is entering a new phase of growth, and a combined R&D organization will accelera.
Read More
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
Read More
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
Published: May 05, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025 at 11:20 am PT (2:20 pm ET). A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after th.
Read More
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.
Read More
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants Tazeen Ahmad – Bank of America Gena Wang – Barclays Teraesa Vitelli – Scotiabank Ellie Merle – UBS Gary Nachman – Raymond James Ritu Baral – TD Cowen Kostas Biliouris – BMO Capital Markets Luca Issi – RBC Capital Markets Paul Matteis – Stifel Mike Ulz – Morgan …
Read More
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a debilitating, rapidly.
Read More
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
Published: March 24, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran).
Read More
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
Read More
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales.
Read More
Alnylam: Waiting For Regulatory Updates In March
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Positive
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows.
Read More
ILMN vs. ALNY: Which Stock Is the Better Value Option?
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Read More
About Alnylam Pharmaceuticals, Inc. (ALNY)
- IPO Date 2004-06-01
- Website https://www.alnylam.com
- Industry Biotechnology
- CEO Dr. Yvonne L. Greenstreet M.B.A., M.D.
- Employees 2230